Abstract 48P
Background
IO-HORIZON aims to provide real-world evidence (RWE) on the profile and treatment patterns of patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving first-line (1L) immuno-oncology (IO) treatment in routine settings in Greece.
Methods
This is an ongoing, non-interventional, prospective study in adults with stage IIIB-IV NSCLC receiving 1L approved IO treatment. Data are collected during routine clinic visits. Baseline results after accrual completion are presented.
Results
From May/2020 to Nov/2021, 240 eligible Caucasian patients (75.4% male, 91.3% ever-smokers) were enrolled by 17 oncology clinics (7 private, 10 public) in Greece. At 1L IO initiation, patients’ median age was 69.0 years, with a median of 2.0 months elapsed since advanced/metastatic disease diagnosis. ECOG performance status was 0/1/2 in 62.5/31.3/6.3%. Disease stage was IIIB/IIIC/IV in 5.0/2.1/92.9%; of the latter patients, 78.5% had de novo stage IV, 23.3% ≥3 metastatic sites, while 36.8% had bone, 17.9% brain, and 16.1% liver metastases. Of the tested patients (n = 226), 73.9% had expressing PD-L1. 1L treatment comprised pembrolizumab + chemotherapy (CT) in 79.2%, pembrolizumab monotherapy in 12.1%, nivolumab + ipilimumab + CT in 6.7%, atezolizumab + bevacizumab + CT in 1.7%, and atezolizumab + CT in one patient (table).
Table: 48PCharacteristics at 1L immunotherapy initiation
| Pembrolizumab | ||||
|---|---|---|---|---|
| Monotherapy | +CT | Nivolumab + ipilimumab + CT | Atezolizumab + CT ± bevacizumab | |
| N = 29 | N = 190 | N = 16 | N = 5 | |
| % of patients | ||||
| Age ≥70 years | 58.6 | 43.2 | 50.0 | 20.0 |
| Male | 65.5 | 76.8 | 81.3 | 60.0 |
| Ever smokers | 75.9 | 93.2 | 93.8 | 100.0 |
| Presence of comorbidity | 62.1 | 74.2 | 50.0 | 60.0 |
| ECOG Performance Status 0-1 | 82.8 | 94.7 | 100.0 | 100.0 |
| Stage IV disease | 75.9 | 94.7 | 100.0 | 100.0 |
| Adenocarcinoma | 62.1 | 72.1 | 31.3 | 100.0 |
| PD-L1 Tumor Proportion Score ≥50% | 96.6 | 21.9 | 14.3 | 20.0 |
Conclusions
These results yield novel RWE on the profile and IO treatment patterns of advanced/metastatic NSCLC patients in Greece. Such data help to better understand disease and therapy approaches so as to design informed health policy strategies.
Clinical trial identification
MK-3475-7755 (IO-HORIZON).
Editorial acknowledgement
Dr Visvikis for his clinical contribution to the study. Qualitis LTD for supporting the abstract write-up.
Legal entity responsible for the study
MSD Greece.
Funding
MSD Greece.
Disclosure
H. Linardou: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, Merck, Takeda, Bristol-Myers Squibb, Eli Lilly, Pfizer; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, Bristol-Myers Squibb, Pfizer, Amgen, Novartis; Financial Interests, Personal and Institutional, Invited Speaker: Bristol-Myers Squibb, Boehringer Ingelheim, Roche, AbbVie, Eli Lilly, Novartis, AstraZeneca, Amgen, PPD, Parexel ILR, Qualitis, Health Data Specialist; Non-Financial Interests, Personal, Principal Investigator: Hellenic Cooperative Oncology Group; Non-Financial Interests, Personal, Leadership Role, Elected President of the Scientific Committee: Hellenic Cooperative Oncology Group; Non-Financial Interests, Personal, Invited Speaker: Women 4 Oncology - Hellas, Fairlife Lung Cancer Care. A. Charpidou: Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, BMS, MSD, Pfizer, Roche. A. Koumarianou: Financial Interests, Personal, Invited Speaker: BMS, Genesis Pharma, Ipsen, Merck, MSD, Novartis, Pfizer, Roche. G. Mountzios: Financial Interests, Personal, Advisory Board: Roche, BMS, Takeda, Janssen; Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, Pfizer, Novartis, Amgen. P.A. Kosmidis: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Other, Registration in Congress: Pfizer; Financial Interests, Personal, Other, Registration to Congress: Sanofi; Financial Interests, Personal, Ownership Interest: Careacross Digital Health Company. C. Christodoulou: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Genesis Pharma, MSD, Novartis, Pfizer, Roche, Sanofi. D. Mavroudis: Financial Interests, Personal, Advisory Board: MSD. A.N. Christopoulou: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, BMS, Glaxo SmithKline, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi. I. Korantzis: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Merck, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi. S. Baka: Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, BMS, Genesis Pharma, Eli Lilly, MSD, Novartis, Roche, Takeda. I. Athanasiadis: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, BMS, Glaxo SmithKline, Ipsen, Eli Lilly, MSD, Novartis, Pfizer, Roche, Servier. A. Koutras: Financial Interests, Personal, Advisory Board: Pierre Fabre, AstraZeneca, Gilead, Pfizer, Genesis; Financial Interests, Personal, Invited Speaker: Sanofi, Gilead; Financial Interests, Personal, Other, travel, accommodations: Rafarm, Eli Lilly, Ipsen, Gilead; Financial Interests, Institutional, Funding: Eli Lilly, Pfizer, Merck; Financial Interests, Institutional, Research Grant: AstraZeneca, Pierre Fabre, BMS, Demo, Faran, Amgen, Roche, Ipsen, Galenica, Win Medica. A. Kotsakis: Financial Interests, Personal, Advisory Role: AstraZeneca, BMS, MSD, Roche. D. Ziogas: Financial Interests, Personal, Invited Speaker: MSD. A. Desiniotis: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ USA. I. Dimitriadis: Financial Interests, Personal, Full or part-time Employment: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ USA. K. Syrigos: Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Pfizer, Roche, Takeda. All other authors have declared no conflicts of interest.